Jan 19, 2026 08:02AM Telo Genomics plans private placement for up to $1.2 million

Jan 19, 2026 08:00AM Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000

Dec 18, 2025 04:05PM Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program

Dec 11, 2025 04:00PM Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting

Nov 13, 2025 08:30AM Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025

Oct 9, 2025 08:30AM American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition

Sep 30, 2025 04:30PM Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update

Sep 19, 2025 08:30AM Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting

Sep 8, 2025 04:20PM Telo Geonomics Announces Engagement of Investor Relations Service Provider

Jul 24, 2025 08:30AM International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting

Jun 30, 2025 06:48PM Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President

Jun 18, 2025 08:30AM Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma

May 27, 2025 08:30AM Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON)

May 15, 2025 08:30AM European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress

Apr 10, 2025 08:30AM Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025

Apr 4, 2025 08:30AM Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors

Mar 12, 2025 08:30AM Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors

Feb 27, 2025 08:30AM Telo Genomics Announces Expanded Partnership with Trusted Health Advisors

Dec 23, 2024 04:00PM Telo Genomics Closes Oversubscribed $2.5 Million Private Placement

Dec 12, 2024 08:45AM Telo Genomics Announces Private Placement for up to $2 Million

Nov 19, 2024 08:45AM Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON)

Oct 30, 2024 08:45AM Telo Genomics Expands its Strategic Collaboration with Mayo Clinic

Oct 22, 2024 08:45AM Telo Genomics Presents New Performance Data for Its Smoldering Myeloma Prognostic Test

Sep 10, 2024 08:45AM Telo Genomics Assessing MRD Status in TELO-DMRD Study

Aug 13, 2024 08:45AM Telo Genomics Receives CLIA Certification

Jun 18, 2024 08:45AM Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP

Jun 12, 2024 08:45AM Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024